‘Time machine’ offers new pancreatic cancer drug testing approach

Drug resistance is a major reason why pancreatic cancer has a five-year survival rate of only about 10%. If scientists tested potential drugs on multiple tumor cell subtypes rather than on just one subtype, they may be able to catch resistance better, suggests a “time machine” developed by Purdue University engineers.